

**Endocrinologic and Metabolic Drugs Advisory Committee and the
Drug Safety and Risk Management Advisory Committee**

July 30, 2007

**Holiday Inn Gaithersburg
Gaithersburg, Maryland**

DRAFT

Meeting Roster

**ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS
(Voting)**

Kenneth D. Burman, M.D.
Chief, Endocrine Section
Washington Hospital Center
Washington, District of Columbia

Katherine M. Flegal, Ph.D.
Senior Research Scientist
Distinguished Consultant
National Center for Health Statistics
Centers for Disease Control and Prevention
Hyattsville, Maryland

Jessica W. Henderson, Ph.D.
Associate Professor, Division of Health and
Physical Education
Western Oregon University
Monmouth, Oregon

Clifford J. Rosen, M.D. [Acting Chair]
Senior Staff Scientist
Maine Center for Osteoporosis
St. Joseph Hospital
Bangor, Maine

**DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBERS
(Voting)**

Sean Hennessy, Pharm.D., Ph.D.
Assistant Professor of Epidemiology
University of Pennsylvania School of
Medicine
Philadelphia, Pennsylvania

Judith M. Kramer, M.D., M.S.
Associate Professor of Medicine
Division of General Internal Medicine and
Clinical Pharmacology
Duke University Medical Center
Durham, North Carolina

Timothy S. Lesar, Pharm.D.
Director of Pharmacy
Albany Medical Center
Albany, New York

TEMPORARY MEMBERS (Voting)

Ruth S. Day, Ph.D.
Director, Medical Cognition Laboratory
Duke University
Durham, North Carolina

Judith Fradkin, M.D.
Director, Division of Diabetes, Endocrinology
& Metabolic Diseases
NIDDK, National Institutes of Health
Bethesda, Maryland

**Endocrinologic and Metabolic Drugs Advisory Committee and the
Drug Safety and Risk Management Advisory Committee**

July 30, 2007

**Holiday Inn Gaithersburg
Gaithersburg, Maryland**

Meeting Roster

**TEMPORARY MEMBERS (Voting)
(Continued)**

Nancy Geller, Ph.D.
Director, Office of Biostatistics Research
NHLBI, National Institutes of Health
Bethesda, Maryland

Allison Goldfine, M.D.
Investigator and Assistant Director of Clinical
Research Section
Joslin Diabetes Center
Boston, Massachusetts

Eric S. Holmboe, M.D., F.A.C.P.
Vice President for Evaluation Research
Director, Clinical Performance Services
American Board of Internal Medicine
Philadelphia, Pennsylvania

Rebecca W. Killion
Patient Representative
Bowie, Maryland

Arthur A. Levin, M.P.H.
Director, Center for Medical Consumers
New York, New York

Arthur Moss, M.D.
Professor of Medicine
Director, Heart Research Follow-up Program
University of Rochester Medical Center
Rochester, New York

Lewis Nelson, M.D., F.A.C.E.P.
Associate Professor, Department of
Emergency Medicine
Director, Medical Toxicology Fellowship
Training Program
New York University School of Medicine and
NYU Hospital Center
New York, New York

David Oakes, Ph.D.
Professor of Biostatistics and Statistics
University of Rochester
Department of Biostatistics and Computational
Biology
Rochester, New York

Thomas G. Pickering, M.D., D.Phil.
Assistant Professor of Medicine
Director, Behavioral Cardiovascular Health
and Hypertension Program
Columbia University Medical Center
New York, New York

Peter J. Savage, M.D.
Division of Epidemiology and clinical
Applications
NHLBI, National Institutes of Health
Bethesda, Maryland

David S. Schade, M.D.
Professor Medicine
Director, Core Laboratory, Vice Chairman for
Research
University of New Mexico School of Medicine
Albuquerque, New Mexico

**Endocrinologic and Metabolic Drugs Advisory Committee and the
Drug Safety and Risk Management Advisory Committee**

July 30, 2007

**Holiday Inn Gaithersburg
Gaithersburg, Maryland**

Meeting Roster

2

**TEMPORARY MEMBERS (Voting)
(Continued)**

Morris Schambelan, M.D.
Chief, Division of Endocrinology
San Francisco General Hospital
San Francisco, California

John R. Teerlink, M.D.
Director, Heart Failure Clinic
Director, Clinical Echocardiography
Cardiology
University of California, San Francisco
San Francisco VA Medical Center
San Francisco, California

Gerald Van Belle, Ph.D.
Professor of Environmental/Occupational
Health Sciences and Biostatistics
University of Washington School of Public
Health & Community Medicine
Department of Environmental and
Occupational Health Sciences
Seattle, Washington

TEMPORARY MEMBERS (Non-Voting)

Curt D. Furberg, M.D., Ph.D.
Professor, Department of Public Health Services
Wake Forest University School of Medicine
Winston-Salem, North Carolina

INDUSTRY REPRESENTATIVES (Non-Voting)

Steven W. Ryder, M.D.
Senior Vice President, Pfizer Global Research
& Development
New London, Connecticut

Annette Stemhagen, Dr.PH.
Vice President, United BioSource Corporation
321 Norristown Road
Ambler, Pennsylvania

GUEST SPEAKER (Non-Voting)

David Gordon, M.D., Ph.D., M.P.H.
Special Assistant for Clinical Studies
Division of Heart & Vascular Diseases
NHLBI, National Institutes of Health
Bethesda, Maryland

Robert E. Ratner, M.D.
Vice-President of Scientific Affairs
MedStar Research Institute
6495 New Hampshire Avenue, Suite 201
Hyattsville, Maryland

**Endocrinologic and Metabolic Drugs Advisory Committee and the
Drug Safety and Risk Management Advisory Committee**

July 30, 2007

**Holiday Inn Gaithersburg
Gaithersburg, Maryland**

DRAFT

Meeting Roster

CONSULTANT (Non-Voting)

Steven Nissen, M.D.
Medical Director, Cleveland Clinic
Cardiovascular Coordinating Center
Department of Cardiovascular Medicine
9500 Euclid Ave.
Cleveland, Ohio

FDA PARTICIPANTS (Non-Voting)

Mark I. Avigan, M.D., M.H.S.
Director, Division of Drug Risk Evaluation
Office of Surveillance and Epidemiology
CDER, FDA

Gerald Dal Pan, M.D., M.H.S.
Director, Office of Surveillance and
Epidemiology
CDER, FDA

Sandra L. Kweder, M.D.
Deputy Director, Office of New Drugs
CDER, FDA

Robert J. Meyer, M.D.
Director, Office of Drug Evaluation II
CDER, FDA

Robert T. O'Neill, Ph.D.
Director, Office of Biostatistics
CDER, FDA

Mary H. Parks, M.D.
Director, Division of Metabolism and
Endocrine Products
CDER, FDA